Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway.
about
Up-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK SignalingThe Importance of Physiologically Relevant Cell Lines for Studying Virus-Host InteractionsIFN-beta-induced alteration of VSV protein phosphorylation in neuronal cells.Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor.Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesMeasles virus suppresses RIG-I-like receptor activation in dendritic cells via DC-SIGN-mediated inhibition of PP1 phosphatasesSuppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells.Effect of human activated NRAS on replication of delNS1 H5N1 influenza virus in MDCK cells.Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA.Mitogen-activated Protein Kinase Kinase 2 (MEK2), a Novel E2-interacting Protein, Promotes the Growth of Classical Swine Fever Virus via Attenuation of the JAK-STAT Signaling Pathway.Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN responseStimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.Colorectal clinical trials: what is on the horizon?RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.The role of signal transducer and activator of transcription-2 in the interferon response.Contribution of Human Fibroblasts and Endothelial Cells to the Hallmarks of Inflammation as Determined by Proteome ProfilingOncogenic Ras inhibits IRF1 to promote viral oncolysis.Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.H-Ras Exerts Opposing Effects on Type I Interferon Responses Depending on Its Activation Status.Global gene analysis identifying genes commonly regulated by the Ras/Raf/MEK and type I IFN pathways.The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K.Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels.Modulation of apoptosis by V protein mumps virus.Analysis of differently expressed proteins and transcripts in gills of Penaeus vannamei after yellow head virus infection.Tumor Restrictions to Oncolytic Virus.The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.A novel MEK2/PI3Kδ pathway controls the expression of IL-1 receptor antagonist in IFN-β-activated human monocytes.Current understanding of reovirus oncolysis mechanisms.
P2860
Q27489886-8835AEFF-8C63-478B-A75C-B7BB615A8803Q28079490-85BEE83D-9D7B-4C09-A025-4F06DBA8E3EEQ30437260-19A756C7-50E9-431E-BA17-2A089A43638EQ33508793-E74ED120-5FFB-45FB-A71B-989B5D60E0ABQ33743847-7599B73E-1648-4C23-A191-C4EE43AAC908Q33924550-C98DA5D5-F5FD-4590-A089-D40E2A47E19BQ34158123-B60E0FDC-5925-47A1-8AEA-0E1F6B76B946Q34412329-9C312C9C-F138-4153-8A5C-F34309A6E1CEQ35040110-12ADF9C8-C457-4BC2-B237-85E7F2E5E328Q35689692-6E2316BE-242C-4B78-AF12-C3A2F643952CQ35876239-85EC56E2-650F-473E-8712-524C89F1DCC5Q36100040-D3E0461A-9B28-4AB6-85AF-713054D788E1Q36125975-76BBE05D-C4D8-4B9C-8C4F-35B14A747774Q36188447-94D67EC5-FDDD-466C-8BB2-CCDD098C1985Q36960705-B4761A9C-F41A-4D32-913F-610CF8978040Q37135340-9C54F020-B74D-4EBC-B871-B054A3282FE9Q37157958-2A64D9B0-EB53-4C53-8EDE-C510FAF4A401Q37247071-FF7DFE47-7562-4686-BDE9-F74DFF2807A0Q37564490-00A7CF05-1617-40A0-B083-1CD71CB362B9Q37565269-68CAD65D-19F6-4CF0-94E4-1A1442206C3DQ37978889-9024C4BC-C3FF-4C70-8D5C-D76FDE16580CQ38394291-8152C345-9689-45F5-B330-B2941C2FB71DQ38944907-8F1A16D7-34AB-457A-B844-9ACF00749CA5Q39212798-346A5E49-7F31-4585-81DC-39668F04183CQ40067130-C2A01A8A-24D2-445E-A3C3-A7C6D8F11311Q40411967-7ED958F7-4F67-4BFC-B677-2F1EBF1B1C89Q40444191-139A18A4-9919-4DC2-AAD7-20D6FF522687Q40613951-0B404D31-2EAA-44BA-88E6-250FB2B63E64Q41359622-0CD94576-DFDD-43F7-8DD0-7752B700D870Q42273321-7D6BB067-2FEA-4EBA-A67A-37396E047D5BQ45400013-FF634254-A713-4C81-9734-91EB99F81330Q51846287-60BFC7CC-D2AD-4A78-8DAC-1D6B5184D27CQ52769266-B754A951-D6F3-4302-8DEE-62C12AD6CC78Q54650268-DCC41AA5-F189-41F9-8A79-E613E7E10EBDQ55427397-B1D34150-3B2B-45FC-B3EE-BF0A4561D168
P2860
Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@en
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@nl
type
label
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@en
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@nl
prefLabel
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@en
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@nl
P2093
P2860
P1433
P1476
Negative regulation of the alp ...... se by the Ras/Raf/MEK pathway.
@en
P2093
Kensuke Hirasawa
Sarah M Battcock
Thaddeus W Collier
P2860
P304
P356
10.1128/JVI.80.9.4422-4430.2006
P407
P577
2006-05-01T00:00:00Z